The present invention relates to compositions comprising a delivery vehicle for delivery of a therapeutic agent for the treatment of a neurological disorder conjugated to a targeting domain, wherein the targeting domain specifically binds to an endothelial marker. The invention also relates to methods of treating or preventing neurological conditions using the described compositions.

The invention provides novel targeted particles as contrast agents for use in molecular imaging of vulnerable plaque, and methods of preparation and application thereof.

Methods are disclosed for treating cancers using antibodies and antibody fragments that inhibit the activity of Vascular cell adhesion molecule 1 (Vcam1) and/or Macrophage erythroblast attacher (Maea).

This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits.

Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an activatable conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.

The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.

An antibody monomer, including an antibody, and a first DNA monomer or a second DNA monomer, where the antibody is an anti-vascular cell adhesion molecule 1 (antiVCAM1) antibody. Nucleotide sequences of the first and second DNA monomers respectively consist of SEQ ID NO:1 and SEQ ID NO:2. A kit including the antibody monomer and an initiator including a nucleotide sequence consisting of SEQ ID NO: 3 is provided. This application also provides a polyvalent antibody including a first antibody monomer and a second antibody monomer, where the first antibody monomer includes the first DNA monomer and the antiVCAM1 antibody, and the second antibody monomer includes the second DNA monomer and the antiVCAM1 antibody. This application further provides a mesenchymal stem cell modified with the antibody monomer or the polyvalent antibody, and an application thereof in the treatment of tissue damage.

A method and device for producing a crude copper. The method comprises: mixing and reacting copper smelting molten slag (1), a carbon-containing reductant (2) and an inert gas (3) under pressure, the pressure of the inert gas (3) being 100 kPa to 800 kPa. The device comprises: a furnace body (4) and gas nozzles (411) disposed on the furnace body (4), the gas nozzles (411) being located on the sidewall of the furnace body (4) and connected to the center of the molten pool.

Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.

The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an activatable conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.